Redox Signaling in Brain Aging and Neurodegeneration

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: 28 September 2025 | Viewed by 826

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biology, University of Padova, Via Ugo Bassi 58/B, 35131 Padova, Italy
Interests: neurodegenerative disease; mitochondrial dysfunction; oxidative stress; Parkinson’s diseases; molecular mechanisms
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Redox signaling is increasingly recognized as a critical factor in brain aging and neurodegenerative diseases. While physiological levels of reactive oxygen and nitrogen species serve as essential signaling molecules, their dysregulation contributes to oxidative stress, mitochondrial dysfunction, proteostasis defects, and neuroinflammation, ultimately leading to neuronal damage. Brain aging is characterized by a gradual decline in antioxidant defenses, rendering neural tissues more susceptible to redox imbalances. This vulnerability is further exacerbated in neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, where disrupted redox signaling intersects with proteostasis alteration, inflammation, and synaptic dysfunction.

This Special Issue explores the intricate mechanisms underlying redox signaling in brain aging and its transition to neurodegenerative states. Key topics include the role of redox-sensitive signaling pathways, the impact of oxidative damage on neuronal networks, and the therapeutic potential of targeting redox imbalance. By integrating insights from molecular biology, neuroscience, and translational research, this issue aims to advance our understanding of redox dynamics in brain health and disease, ultimately paving the way for innovative approaches to mitigate neurodegeneration and promote healthy aging.

Dr. Marco Bisaglia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • aging
  • autophagy
  • brain
  • Alzheimer disease
  • amyotrophic lateral sclerosis
  • Friedreich ataxia
  • Huntington disease
  • neurodegeneration
  • oxidative stress
  • protein aggregation
  • Parkinson’s disease
  • reactive oxygen species

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 1096 KiB  
Article
Subchronic Intranasal Administration of NeuroEPO Reduces Long-Term Consequences of Severe Traumatic Brain Injury in Male Rats
by Félix Iván López-Preza, Maria de los Angeles Nuñez-Lumbreras, Iliana Sosa-Testé, Alonso Fernández-Guasti, Luis Concha, Teresita Rodríguez-Obaya and Luisa Rocha
Antioxidants 2025, 14(6), 710; https://doi.org/10.3390/antiox14060710 - 11 Jun 2025
Viewed by 616
Abstract
Current treatments fail to prevent long-term consequences induced by a severe traumatic brain injury (TBI). This study aimed to evaluate the efficacy of repetitive intranasal administration of NeuroEPO (a derivative of erythropoietin) on long-term alterations after a severe TBI induced by the application [...] Read more.
Current treatments fail to prevent long-term consequences induced by a severe traumatic brain injury (TBI). This study aimed to evaluate the efficacy of repetitive intranasal administration of NeuroEPO (a derivative of erythropoietin) on long-term alterations after a severe TBI induced by the application of a lateral fluid percussion in male rats. A otal of 30–31 days after the trauma, TBI+vehicle group showed sensorimotor dysfunction (Neuroscore, p < 0.0009; beam walking test, p < 0.0001 vs. Sham+vehicle group) and depressive-like behavior suggested by increased immobility (p = 0.0009 vs. baseline) during the forced swim test. Rats also showed increased production of malondialdehyde (a marker of oxidative damage), increased catalase activity (an antioxidant enzyme), and atrophy of brain areas evaluated with Magnetic Resonance Imaging 31 days after the trauma. TBI+NeuroEPO group received intranasal administration of NeuroEPO (0.136 mg/kg) starting 3 h post-TBI and continued every 8 h for four days. This group showed less sensorimotor dysfunction (Neuroscore, p = 0.020; beam walking test, p = 0.001, vs. TBI+vehicle group) and normal immobility behavior (p = 0.998 vs. Sham+vehicle group). Levels of malondialdehyde and catalase as well as the volume of brain structures of this group were like the Sham+vehicle group. These findings support the potential of NeuroEPO as a therapeutic agent to reduce long-term consequences of TBI. Full article
(This article belongs to the Special Issue Redox Signaling in Brain Aging and Neurodegeneration)
Show Figures

Figure 1

Back to TopTop